New England Journal of Medicine· 2023Q1

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

A. Michael Lincoff, Kirstine Brown‐Frandsen, Helen M. Colhoun, John Deanfield et al.

2,717citations
Q1SCImago
2023year

Short summary

Weekly 2.4 mg semaglutide reduced major adverse cardiovascular events by 20% (HR 0.80) compared to placebo in overweight or obese adults with pre-existing cardiovascular disease but no diabetes.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Endocrinology, Diabetes and Metabolism

Endocrinology, Diabetes and MetabolismMedicine